TABLE 1.

Baseline demographics

Variable	Time posttransplant at study enrolment			P
	All patients(N = 51)	≤5 ypost-TXP(N = 29)	>5 ypost-TXP(N = 22)
Time posttransplant at enrolment, d	1762(1104–2563)	1149(969–1492)	2796(2191–3405)	<0.01
Age at transplant, y	58 (50–62)	59 (51–63)	58 (47–61)	0.55
Female sex	20 (39)	13 (45)	7 (32)	0.40
Bilateral transplant	43 (84)	23 (79)	20 (91)	0.44
White race	43 (84)	24 (83)	19 (86)	1.0
Body mass index at transplant	25.4 (20.6–27.8)	23.2 (20.4–27.5)	26.4 (23.1–28.3)	0.25
Lung allocation score at transplant	39.5 (36.0–52.4)	39.0 (35.8–52.0)	40.0 (37.7–52.4)	0.47
CMV D+/R−	12 (24)	4 (14)	8 (36)	0.10
Diagnosis group				0.47
Obstructive	13 (25)	8 (28)	5 (23)
Pulmonary vascular	3 (6)	2 (10)	1 (5)
Cystic fibrosis	2 (4)	2 (10)	0
Interstitial	33 (65)	17 (59)	16 (73)
Total ischemic time, h	5.46 (4.43–6.15)	5.8 (4.22–6.33)	5.28 (4.96–5.82)	0.71
Gastroesophageal reflux diagnosis posttransplant	27 (53)	16 (55)	11 (50)	0.78
Esophageal dysmotility	11 (22)	5 (20)	6 (27)	0.50
Primary graft dysfunction grade 3 at 72 h posttransplant	5 (10)	4 (15)	1 (11)	0.38
Acute cellular rejection history	33 (65)	15 (50)	18 (82)	0.04
De novo donor-specific antibody (MFI >3000)	8 (16)	5 (17)	3 (16)	1.0

Patients who underwent ≥3 assessments of donor-derived, cell-free DNA, each separated by >1 mo, who were asymptomatic with stable forced expiratory volume in 1 s were included (N = 51). Categorical values are expressed as number (%) and compared using the Pearson chi-square test vs the Fisher exact test, where appropriate. Continuous values are expressed as median (interquartile range) and compared using the Mann-Whitney U test or the Kruskal-Wallis test, where appropriate.

CMV, cytomegalovirus; D, donor; MFI, mean fluorescent intensity; R, recipient; TXP, transplant.